NFKB1 and neoplasm: At the cellular level, deploy CRISPR/Cas9 knock-out/knock-in and CRISPRa/i of F2RL1 with biosensor read-outs for Gq/11, G12/13, ERK, NF-κB, and β-arrestin (BRET/FRET) to map biased PAR-2 transduction under EGCG, FXa, trypsin/tryptase, and tumor-derived protease milieus.